癌症肽疗法新星冲刺纳斯达克！Parabilis(PBLS.US)拟募资4.5亿美元以26亿美元市值登陆美股

智通财经06-04

智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines在美东时间6月3日确定4.5亿美元IPO条款。Parabilis Medicines是一家处于临床试验阶段、开发用于癌症治疗的工程化肽疗法的生物科技公司，这家总部位于马萨诸塞州剑桥的公司计划通过以每股17美元至19美元的价格区间发行2500万股股票，来筹集大约4.5亿美元。按拟议区间的中点计算，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2640153656?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-04 16:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2640153656","market":"sh","top_or_hot":-1,"title":"癌症肽疗法新星冲刺纳斯达克！Parabilis(PBLS.US)拟募资4.5亿美元 以26亿美元市值登陆美股","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines在美东时间6月3日确定4.5亿美元IPO条款。Parabilis Medicines是一家处于临床试验阶段、开发用于癌症治疗的工程化肽疗法的生物科技公司，这家总部位于马萨诸塞州剑桥的公司计划通过以每股17美元至19美元的价格区间发行2500万股股票，来筹集大约4.5亿美元。按拟议区间的中点计算，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1450121.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>癌症肽疗法新星冲刺纳斯达克！Parabilis(PBLS.US)拟募资4.5亿美元 以26亿美元市值登陆美股</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n癌症肽疗法新星冲刺纳斯达克！Parabilis(PBLS.US)拟募资4.5亿美元 以26亿美元市值登陆美股\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-04 16:39 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1450121.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines在美东时间6月3日确定4.5亿美元IPO条款。Parabilis Medicines是一家处于临床试验阶段、开发用于癌症治疗的工程化肽疗法的生物科技公司，这家总部位于马萨诸塞州剑桥的公司计划通过以每股17美元至19美元的价格区间发行2500万股股票，来筹集大约4.5亿美元。按拟议区间的中点计算，...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1450121.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NAPR","symbol_name":"Innovator Growth-100 Power Buffer ETF - April","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1450121.html","article_id":"2640153656","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640153656","pubTimestamp":1780562365,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines在美东时间6月3日确定4.5亿美元IPO条款。按拟议区间的中点计算，Parabilis Medicines 的市值将达到 26亿美元。Parabilis Medicines 是一家处于临床阶段的生物科技公司，开发靶向此前被认为“不可成药”的蛋白质的药物。Parabilis此前已经获得华尔街金融巨头Fidelity和RA Capital支持，已通过私募融资筹集近10亿美元，最近一次是在1月的F轮融资中筹集超过3亿美元。Parabilis Medicines成立于2015年。该公司计划在纳斯达克以代码“PBLS”上市。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159632":"纳斯达克","NAPR":"Innovator Growth-100 Power Buffer ETF - April","QQQE":"Direxion NASDAQ-100 Equal Weighted Index Shares","JEPQ":"JPMorgan Nasdaq Equity Premium Income ETF","TECS":"Direxion Daily Technology Bear 3X Shares","NVIW.SI":"NVDA 3xLongSG261006","QQQX":"Nuveen NASDAQ 100 Dynamic Overwrite","07266":"南方两倍做多纳指","03086":"华夏纳指",".IXIC":"NASDAQ Composite","09086":"华夏纳指-U","QQQY":"Defiance Nasdaq 100 Enhanced Options & 0DTE Income ETF","03455":"景顺QQQ","GPIQ":"GOLDMAN SACHS NASDAQ 100 CORE PREMIUM INCOME ETF","QID":"两倍做空纳斯达克指数ETF-ProShares","09834":"安硕纳指一百—U","QYLG":"Nasdaq 100 Covered Call & Growth ETF","07522":"FI二华夏纳一百","PSQ":"做空纳斯达克100指数ETF-ProShares","QMAR":"FT Vest Nasdaq-100 Buffer ETF - March","QDEC":"FT Vest Nasdaq-100 Buffer ETF - December","QLD":"2倍做多纳斯达克100指数ETF-ProShares","TQQY":"GraniteShares YieldBOOST QQQ ETF","NJAN":"Innovator Growth-100 Power Buffer ETF - January","QQQJ":"Invesco NASDAQ Next Gen 100 ETF","07568":"FI二南方纳指","SQQQ":"纳指三倍做空ETF","TQQQ":"纳指三倍做多ETF","ONEQ":"Fidelity NASDAQ Composite Index ETF","BK4007":"制药","03034":"南方纳指一百","QQQM":"NASDAQ100指数ETF-Invesco","02834":"安硕纳指一百","NJUL":"Innovator Growth-100 Power Buffer ETF - July","FTEC":"Fidelity MSCI Information Techno","IYW":"美国科技ETF-iShares","NDX":"纳斯达克100指数","ARTL":"Artelo Biosciences, Inc.","QQQ":"纳指100ETF","QQQA":"ProShares Nasdaq-100 Dorsey Wright Momentum ETF","BK1147":"投资银行业与经纪业","NOCT":"Innovator Growth-100 Power Buffer ETF - October","QDTE":"Roundhill N-100 0DTE Covered Call Strategy ETF","07261":"FL二华夏纳一百"},"translate_title":"Cancer Peptide Therapy Rising Stars Sprint Nasdaq! Parabilis (PBLS.US) to raise $450 million to land in U.S. stocks with a market cap of $2.6 billion","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/2a9c59b98f5aa9b1496811cd29d4c852","symbols_score_info":{"159632":1.5,"02834":0.6,"FTEC":0.6,"07522":0.6,"QMAR":0.6,"QQQE":0.6,"07568":0.6,"07266":0.6,"MNQmain":0.6,"03034":0.6,"IYW":0.6,"NVIW.SI":0.6,"QID":0.6,"QQQA":0.6,"QDTE":0.6,"QQQX":0.6,"09086":0.6,"ARTL":1.5,"SQQQ":0.6,"03455":0.6,"09834":0.6,"JEPQ":0.6,"QLD":0.6,"TQQY":0.6,"NQmain":1.5,"TQQQ":0.6,"QQQ":0.6,"ONEQ":0.6,"NOCT":0.6,"GPIQ":0.6,"NJUL":0.6,"TECS":0.6,"03086":1.5,"QYLG":0.6,"QQQY":0.6,"07261":0.6,"NJAN":0.6,"NAPR":0.6,"QQQM":0.6,"NDX":1.5,".IXIC":1.5,"PSQ":0.6,"QDEC":0.6,"QQQJ":0.6},"content_text":"智通财经APP获悉，聚焦癌症治疗的美国生物科技公司Parabilis Medicines在美东时间6月3日确定4.5亿美元IPO条款。Parabilis Medicines是一家处于临床试验阶段、开发用于癌症治疗的工程化肽疗法的生物科技公司，这家总部位于马萨诸塞州剑桥的公司计划通过以每股17美元至19美元的价格区间发行2500万股股票，来筹集大约4.5亿美元。按拟议区间的中点计算，Parabilis Medicines 的市值将达到 26亿美元。Parabilis Medicines 是一家处于临床阶段的生物科技公司，开发靶向此前被认为“不可成药”的蛋白质的药物。该公司此前名为FOG Pharmaceuticals，其专有Helicon平台可生产稳定化螺旋肽，旨在调节传统小分子或生物制剂无法触及的细胞内蛋白相互作用。其主要候选药物zolucatetide 靶向Wnt/β-catenin通路，该通路驱动广泛的实体瘤;迄今已有超过150名患者接受了zolucatetide给药。Pharmaceuticals核心技术不是传统小分子、抗体或细胞疗法，而是其专有 Helicon™稳定化螺旋肽平台：通过工程化肽分子进入细胞内，调控过去被认为“不可成药”的蛋白—蛋白相互作用，尤其瞄准传统药物难以覆盖的细胞内癌症驱动靶点。公司官网称，其Helicon疗法属于“alpha-helically locked peptides”，并结合AI与物理计算方法进行设计优化。在其主要适应症硬纤维瘤的临床试验中，已有38名患者入组并接受zolucatetide治疗;在25名随访充分、可评估疗效反应的患者群体中，全部25名(100%)均显示肿瘤缩小，而在19名完成两次基线后扫描的患者中，有14名(74%)按照RECIST 1.1标准达到客观缓解。该公司计划在 2027年上半年启动针对硬纤维瘤的3期注册性临床试验。该公司还在评估 zolucatetide作为孤儿病家族性腺瘤性息肉病(FAP)治疗方案的潜力。Parabilis此前已经获得华尔街金融巨头Fidelity和RA Capital支持，已通过私募融资筹集近10亿美元，最近一次是在1月的F轮融资中筹集超过3亿美元。Parabilis Medicines成立于2015年。该公司计划在纳斯达克以代码“PBLS”上市。Leerink Partners、美国银行证券(BofA Securities)、Evercore ISI、Guggenheim Securities以及LifeSci Capital 是此次交易的联合账簿管理人。该交易预计将在2026年6月8日当周定价。这家聚焦癌症治疗的新锐临床阶段生物科技公司目前仍处于临床阶段，核心增长路径不是现有药品销售收入，而是未来药物获批后的商业化收入、适应症扩展、平台管线开发以及对外合作授权。其IPO融资逻辑主要围绕三点：推进zolucatetide后期临床、扩大Helicon平台在“不可成药”靶点中的应用、并通过与大型药企合作兑现平台价值;例如公司已与Regeneron达成战略合作，将Helicon肽平台与Regeneron抗体能力结合，开发新型Antibody-Helicon™ Conjugates。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2640153656","isCrawlerRequest":true}

癌症肽疗法新星冲刺纳斯达克！Parabilis(PBLS.US)拟募资4.5亿美元 以26亿美元市值登陆美股

精彩评论

癌症肽疗法新星冲刺纳斯达克！Parabilis(PBLS.US)拟募资4.5亿美元以26亿美元市值登陆美股